New study aims to improve inhaler treatment for lung fungus
NCT ID NCT07530263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well an inhaled antifungal drug (liposomal amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis, a long-term lung infection. About 18 adults will inhale two different doses on separate days and then have special scans to see where the drug goes in their lungs. The goal is to find the best dose and delivery method, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PULMONARY ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radboudumc
Nijmegen, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.